Trends in the use of routine therapies in cystic fibrosis: 1995-2005

Pediatric Pulmonology

Volumn 45, Issue 12, 2010, Pages 1167-1172

  Konstan, Michael W ^a   Vandevanter, Donald R ^a   Rasouliyan, Lawrence ^b   Pasta, David J ^b   Yegin, Ashley ^c   Morgan, Wayne J ^d   Wagener, Jeffrey S ^e  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ICON CLINICAL RESEARCH   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

cystic fibrosis; epidemiology; therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DORNASE ALFA; IBUPROFEN; INSULIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; MUCOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PANCREAS ENZYME; SODIUM CHLORIDE;

ADOLESCENT; ARTICLE; CYSTIC FIBROSIS; DRUG MEGADOSE; ENTERIC FEEDING; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CLEARANCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHODILATOR AGENTS; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DIETARY SUPPLEMENTS; DRUG UTILIZATION; ENTERAL NUTRITION; EXPECTORANTS; FORCED EXPIRATORY VOLUME; HUMANS; HYPOGLYCEMIC AGENTS; LEUKOTRIENE ANTAGONISTS; LONGITUDINAL STUDIES; NORTH AMERICA; OXYGEN INHALATION THERAPY; PROSPECTIVE STUDIES; SALINE SOLUTION, HYPERTONIC;

EID: 78649647554     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21315     Document Type: Article

References (9)

1. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Jr., Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B,. Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-969.
2. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H,. Clinical Practice Guidelines on Growth and Nutrition Subcommittee; Ad Hoc Working Group. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008; 108: 832-839.
3. Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA, for the investigators and coordinators of the Epidemiologic Study of Cystic Fibrosis. Patterns of medical practice in cystic fibrosis: Part II. Use of therapies. Pediatr Pulmonol 1999; 28: 248-254.
4. Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, Konstan MW, Light MJ, Rabin HR, Regelmann WE, Schidlow DV, Stokes DC, Wohl ME, Kaplowitz H, Wyatt MM, Stryker S,. Epidemiologic Study of Cystic Fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999; 28: 231-241.
5. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG,. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15: 75-88.
6. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-187.
7. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2008 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2009.
8. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW, Pulmozyme Early Intervention Trial Study Group. The Pulmozyme Early Intervention Trial study group: a two-year randomized, placebo controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-820.
9. VanDevanter DR, Rasouliyan LH, Murphy TM, Morgan WJ, Ren CL, Konstan MW, Wagener JS, for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol 2008; 43: 739-744.